Core Viewpoint - China Resources Sanjiu announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) through negotiations, marking a significant milestone for the company [1] Group 1: Drug Registration and Classification - Yiqi Qingfei Granules is classified as a Traditional Chinese Medicine (TCM) under category 3.2, with a dosage form of granules [1] - The drug received its registration certificate from the National Medical Products Administration in January 2025 [1] Group 2: Agreement and Validity - The agreement for inclusion in the insurance drug list is effective from January 1, 2026, to December 31, 2027 [1] - The indications for Yiqi Qingfei Granules include nourishing Qi and Yin, strengthening the spleen, and clearing heat and dampness [1] Group 3: Market Activities - The company is currently engaged in post-marketing academic promotion and related activities for online sales [1]

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory (2025 version), which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market position [1][3]. Product Information - Product Name: Yiqi Qingfei Granules - Drug Classification Code: ZA09G - Drug Type: Traditional Chinese Medicine (TCM) - Registration Category: TCM Class 3.2 - Dosage Form: Granules - Agreement Validity: January 1, 2026, to December 31, 2027 - Indications: Used for symptoms related to Qi and Yin deficiency, spleen deficiency, and dampness, including fatigue, shortness of breath, dry cough, and gastrointestinal discomfort [1][2]. Impact on the Company - Yiqi Qingfei Granules received its drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and sales activities. The inclusion in the National Medical Insurance Directory is expected to have a positive impact on the company's product layout in the respiratory field, although it is not anticipated to significantly affect short-term operating performance [3].

Core Viewpoint - China Resources Sanjiu (华润三九) has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory, which is expected to enhance its product portfolio in the respiratory field, although it is not anticipated to have a significant short-term impact on the company's financial performance [1]. Group 1: Company Performance - As of December 8, 2025, China Resources Sanjiu's stock closed at 28.15 yuan, down 0.49% from the previous trading day, with a total market capitalization of 46.848 billion yuan [1]. - The stock opened at 28.3 yuan, reached a high of 28.39 yuan, and a low of 28.1 yuan, with a trading volume of 2.25 billion yuan and a turnover rate of 0.48% [1]. Group 2: Product Development - Yiqi Qingfei Granules, classified as a traditional Chinese medicine (Category 3.2), is indicated for short-term symptoms following epidemics related to Qi and Yin deficiency, spleen deficiency, and residual pathogenic factors [1]. - The product was approved for market launch in January 2025 and is currently undergoing post-market academic promotion and online sales [1]. - Inclusion in the National Medical Insurance Directory will take effect from January 1, 2026, with the agreement valid until December 31, 2027 [1].

Core Viewpoint - The company Huazhu Sanjiu announced that its drug Yiqi Qingfei Granules has been included in the National Medical Insurance Directory (2025 version) for the first time [1][2] Group 1: Product Approval and Market Entry - Yiqi Qingfei Granules received the Drug Registration Certificate from the National Medical Products Administration, officially approved for market launch in January 2025 [1][2] - The company is currently conducting academic promotion and online sales activities for Yiqi Qingfei Granules in an orderly manner [1][2]

公告显示，益气清肺颗粒于2025年1月获得国家药品监督管理局颁发的《药品注册证书》，正式获批上 市。适应症为益气养阴，健脾和中，清热祛湿，适用于疫病后短期症状，气阴两虚，脾虚失运，余邪未 尽证，症见倦怠乏力、动后气短、干咳少痰、咽喉不利、胃脘痞闷、纳呆便溏，舌淡或红、少津，脉细 数。 北京商报讯（记者 王寅浩 宋雨盈）12月8日，华润三九发布公告称，公司药品益气清肺颗粒通过谈判首 次纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》，协议有效期为2026年1月1日 至2027年12月31日。 ...

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The 2025 version of the National Medical Insurance Catalog will officially take effect on January 1, 2026, marking the first inclusion of Yiqi Qingfei Granules in this catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory product sector [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations [1] Group 1 - The inclusion of Yiqi Qingfei Granules marks a significant milestone for the company, enhancing its market access and potential revenue streams [1] - This decision is part of a broader initiative by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security to update the drug catalog [1]

Core Viewpoint - China Resources Sanjiu (000999.SZ) announced that its drug Yiqi Qingfei Granules has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025 through negotiations, as per the notice from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The inclusion of Yiqi Qingfei Granules in the National Drug Catalog marks a significant milestone for the company [1] - This development is expected to enhance the accessibility of the drug to a broader patient population under the national insurance scheme [1] - The decision reflects the government's ongoing efforts to improve healthcare coverage and access to innovative treatments [1]

Core Viewpoint - China Resources Sanjiu Pharmaceutical Co., Ltd. has successfully included its product Yiqi Qingfei Granules in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025 version) through negotiations, which is expected to enhance the company's product portfolio in the respiratory field and strengthen its market leadership position [1] Group 1 - Yiqi Qingfei Granules received the drug registration certificate from the National Medical Products Administration in January 2025 and is currently undergoing post-market academic promotion and online sales [1] - The National Medical Insurance Catalog (2025 version) will officially take effect on January 1, 2026, marking the first inclusion of this drug in the catalog [1] - The short-term impact on the company's operating performance is not expected to be significant, but the inclusion is seen as a positive step for the company's strategic positioning in the respiratory sector [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released the new basic medical insurance drug list for 2025, which will take effect on January 1, 2026, leading to a significant increase in the success rate of new drug negotiations, particularly for innovative drugs with high clinical value [1][2]. Group 1: New Drug Negotiation Success - The success rate for new drug negotiations in 2025 has significantly improved to 88%, up from 76% in 2024, with 114 new drugs added to the national medical insurance drug list, including 50 Class 1 innovative drugs [2][3]. - The total number of drugs in the national medical insurance drug list has increased to 3,253, enhancing coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [2]. Group 2: Unique Drug Inclusion - Among the 114 newly added drugs, 105 are unique varieties, representing 92.11% of the total, including 98 Western medicines and 7 traditional Chinese medicines [3]. - The inclusion of unique traditional Chinese medicines from companies like China Resources Sanjiu, Yiling Pharmaceutical, and others indicates a balanced representation in the new drug list [3]. Group 3: Market Potential and Growth - The inclusion of 116 drugs in the latest negotiation, particularly 11 new drugs from Heng Rui Medicine and others, is expected to lead to rapid market share growth and product volume increase due to their entry into the medical insurance directory [4][5]. - The negotiation also included new mechanism drugs, such as antibody-drug conjugates and small nucleic acid siRNA drugs, which are anticipated to drive market penetration and accessibility [5]. Group 4: Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory saw intense competition, with 121 candidates but only 24 entering negotiations, resulting in 19 drugs being successfully included [6]. - The directory covers critical diseases such as Alzheimer's and multiple myeloma, with a balanced mix of imported and domestic drugs [6]. Group 5: Investment Recommendations - Companies with a significant number of innovative drugs included in the new medical insurance directory, such as Heng Rui Medicine, BeiGene, and others, are recommended for investment [9]. - Potential growth in traditional Chinese medicine products included in the new directory, such as those from China Resources Sanjiu and Yiling Pharmaceutical, is also highlighted [9].